title: [Clinical results of a rokitamycin dry syrup in pediatric infections].
abstract: Clinical efficacies of a new macrolide antibiotic, rokitamycin (RKM, TMS-19-Q), were studied in acute pediatric infections. Responses to the RKM administration were evaluable in 62 out of 68 patients consisted of 7 patients with pharyngitis (efficacy rate of 85.7%, 6/7 patients), 4 with bronchitis (25.0%, 1/4), 9 with tonsillitis (100%, 9/9), 13 with mycoplasmal pneumonia (100%, 13/13), 13 with hemolytic streptococcal infections (92.3%, 12/13), 14 with pneumonia (57.1%, 8/14), one with pertussis (100%, 1/1) and another with Chlamydia pneumonia (100%, 1/1) thus an overall efficacy rate of 82.3% was achieved. Urticaria was observed in one of the patients as an adverse reaction to the drug, while abnormal laboratory test results were noted in 3 patients, but none of such changes were severe. The drug, even when administered in combination with a theophylline preparation, exerted no effects on the serum concentration of the latter.
authors.affiliation: Department of Pediatrics, School of Medicine, Hirosaki University.
authors.forename: K
authors.initials: K
authors.lastname: Kawauchi
authors.forename: Y
authors.initials: Y
authors.lastname: Sato
authors.forename: S
authors.initials: S
authors.lastname: Kimura
authors.forename: S
authors.initials: S
authors.lastname: Yonesaka
authors.forename: M
authors.initials: M
authors.lastname: Yokoyama
authors.forename: A
authors.initials: A
authors.lastname: Onishi
authors.forename: T
authors.initials: T
authors.lastname: Asuka
authors.forename: T
authors.initials: T
authors.lastname: Okamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Takebe
authors.forename: T
authors.initials: T
authors.lastname: Tsushima
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007933:Leucomycins / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D015644:Miocamycin / Q000031:analogs & derivatives*; D013806:Theophylline / Q000378:metabolism; D014581:Urticaria / Q000139:chemically induced
chemical_list: D007933:Leucomycins; D015644:Miocamycin; D013806:Theophylline; C033383:rokitamycin